Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-8591A PK in healthy lactating females
NCT07086079Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of doravirine and islatravir in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Cumulative Amount of DOR Excreted in Breast Milk From 0 to 24 Hours, Body Weight Normalized Infant Theoretical Dose of DOR at 24 hours and 4 more. Started Sep 2025; status: completed.
02
Drugs
doravirineislatravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07086079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086079.